We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novel Target for a Type of Pediatric Brain Tumor Identified
News

Novel Target for a Type of Pediatric Brain Tumor Identified

Novel Target for a Type of Pediatric Brain Tumor Identified
News

Novel Target for a Type of Pediatric Brain Tumor Identified

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novel Target for a Type of Pediatric Brain Tumor Identified"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Investigators at St. Jude Children's Research Hospital have found that the ABCC4 transporter is critical to the SHH signaling pathway in the brain tumor medulloblastoma. This work provides a rationale for development of small molecule inhibitors that target ABCC4. The findings appeared in Cancer Research.

Medulloblastoma is the most common malignant pediatric brain tumor. There are four genomic subgroups of the disease: WNT, SHH, Group 3 and Group 4. The SHH subgroup accounts for about 25% of all pediatric medulloblastoma cases. The five-year survival rate for SHH medulloblastoma is approximately 75%.

Transporters are proteins found on the cell membrane. They help substances enter and exit cells. The researchers found that the ABCC4 transporter is highly expressed in SHH medulloblastoma.

"We have studied the ABCC4 transporter for many years, and wanted to better understand how it interacts with critical pathways that drive tumor growth, like SHH," said senior author John Schuetz, Ph.D., of the St. Jude Department of Pharmaceutical Sciences. "By teasing apart the relationship between ABCC4 and the SHH pathway, we've identified a novel strategy for potentially treating these tumors."

The researchers built a medulloblastoma "interactome" to determine which proteins interact with and are essential to the SHH pathway. The findings showed that ABCC4 is highly expressed in the SHH subgroup and is required for optimal activation of the pathway.

The researchers found that increased expression of ABCC4 correlates with poor overall survival in SHH medulloblastoma. Targeting ABCC4 using genomic methods reduced the size of medulloblastoma tumors and extended the lifespan of mouse models.

"By following the web of interactions between different parts of key tumor pathways, we can take a more targeted approach to cancer therapy," said first author Juwina Wijaya, Ph.D., formerly a postdoctoral fellow in Schuetz's laboratory. "We now know another one of SHH medulloblastoma's weaknesses."

Reference: Wijaya, et al. (2020) An ABC transporter drives medulloblastoma pathogenesis by regulating Sonic Hedgehog signaling. Cancer Research DOI: 10.1158/0008-5472.CAN-19-2054

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement